文献速递血栓与止血

小鼠体内生长的人胰腺肿瘤释放组织因子阳性微囊泡,增加静脉血栓体积

Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size.
PubMed 文献 · J Thromb Haemost · 2017-09-20

在裸鼠原位移植人胰腺肿瘤模型中,荷瘤小鼠静脉血栓显著大于对照小鼠,血栓中可检测到人组织因子,提示肿瘤来源微囊泡掺入;给予抗人组织因子单克隆抗体可减小荷瘤小鼠血栓体积,而对对照小鼠无影响。结果表明肿瘤释放的组织因子阳性微囊泡可增强小鼠静脉血栓形成。

要点

  • 荷瘤小鼠静脉血栓显著大于对照小鼠。
  • 荷瘤小鼠血栓中含人组织因子,提示肿瘤来源微囊泡掺入。
  • 抗人组织因子单克隆抗体减小荷瘤小鼠血栓体积,对照小鼠无变化。

核心结论

  • 原位胰腺肿瘤释放的组织因子阳性微囊泡增加小鼠静脉血栓形成。
  • 该新模型可能有助于评估癌症相关血栓形成中不同因素的作用。

研究设计与样本

  • 在裸鼠原位移植人胰腺肿瘤,采用下腔静脉淤滞模型诱导静脉血栓。
  • 使用抗人组织因子单克隆抗体评估肿瘤来源组织因子阳性微囊泡对血栓形成的贡献。

主要发现

  • 荷瘤小鼠血栓显著大于对照小鼠。
  • 荷瘤小鼠血栓含人组织因子,提示肿瘤来源微囊泡掺入。
  • 给予抗人组织因子单克隆抗体可减小荷瘤小鼠血栓体积,对对照小鼠血栓体积无影响。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Tumor-bearing mice have larger venous clots than controls. Human tissue factor is present in clots in tumor-bearing mice. Inhibition of human tissue factor reduces clot size in tumor-bearing mice. This new mouse model may be useful to study mechanisms of cancer-associated thrombosis. SUMMARY: Background Pancreatic cancer patients have a high rate of venous thromboembolism. Human pancreatic tumors and cell lines express high levels of tissue factor (TF), and release TF-positive microvesicles (TF+ MVs). In pancreatic cancer patients, tumor-derived TF+ MVs are present in the blood, and increased levels are associated with venous thromboembolism and decreased survival. Previous studies have shown that mice with orthotopic human or murine pancreatic tumors have circulating tumor-derived TF+ MVs, an activated clotting system, and increased incidence and mean clot weight in an inferior vena cava stenosis model. These results suggest that TF+ MVs contribute to thrombosis. However, the specific role of tumor-derived TF+ MVs in venous thrombosis in mice has not been determined. Objectives To test the hypothesis that tumor-derived TF+ MVs enhance thrombosis in mice. Methods We determined the contribution of TF+ MVs derived from human pancreatic tumors grown orthotopically in nude mice to venous clot formation by using an anti-human TF mAb. We used an inferior vena cava stasis model of venous thrombosis. Results Tumor-bearing mice had significantly larger clots than control mice. Clots from tumor-bearing mice contained human TF, suggesting the incorporation of tumor-derived MVs. Importantly, administration of an anti-human TF mAb reduced clot size in tumor-bearing mice but did not affect clot size in control mice. Conclusions Our results indicate that TF+ MVs released from orthotopic pancreatic tumors increase venous thrombosis in mice. This new model may be useful for evaluating the roles of different factors in cancer-associated thrombosis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hisada Y, Ay C, Auriemma AC, et al. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost. 2017. PMID: 28834179. doi:10.1111/jth.13809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。